The United States Food and Drug Administration (USFDA) has completed inspection Aurobindo Pharma’s Unit XIV, an API Non antibiotic Manufacturing facility situated at Paravada Industrial Area, Anakapalli District. Andhra Pradesh, from May 15 to May 19 2023. At the end of the inspection, The company has been issued a 'Form 483' with four observations. The observations are procedural in nature.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
